[{"id":"5ab5758f-ded0-479b-83dd-b16b495d0f1a","acronym":"FASCINATE-N","url":"https://clinicaltrials.gov/study/NCT05582499","created_at":"2022-10-17T13:56:00.115Z","updated_at":"2025-02-25T12:29:07.250Z","phase":"Phase 2","brief_title":"Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy","source_id_and_acronym":"NCT05582499 - FASCINATE-N","lead_sponsor":"Fudan University","biomarkers":" HER-2 • PGR • CD8 • FOXC1","pipe":"","alterations":" ","tags":["HER-2 • PGR • CD8 • FOXC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • carboplatin • Perjeta (pertuzumab) • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • Irene (pyrotinib) • albumin-bound paclitaxel • cyclophosphamide • letrozole • epirubicin • trastuzumab rezetecan (SHR-A1811) • AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib) • goserelin acetate • famitinib (SHR 1020) • AiRuiLi (adebrelimab) • tizetatug rezetecan (SHR-A1921)"],"overall_status":"Recruiting","enrollment":" Enrollment 716","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-12-27"},{"id":"d794956d-7d72-4864-b172-3cc363bc86b3","acronym":"","url":"https://clinicaltrials.gov/study/NCT06649331","created_at":"2025-02-26T09:16:39.825Z","updated_at":"2025-02-26T09:16:39.825Z","phase":"Phase 2","brief_title":"Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer","source_id_and_acronym":"NCT06649331","lead_sponsor":"Fudan University","biomarkers":" HER-2 • NECTIN4 • TACSTD2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2 • NECTIN4 • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e trastuzumab rezetecan (SHR-A1811) • SHR-A2102 • ruzaltatug rezetecan (SHR-A2009) • tizetatug rezetecan (SHR-A1921)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 10/21/2024","start_date":" 10/21/2024","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2024-12-10"},{"id":"07acdaee-81fa-42a2-b6a8-44ffa1343ca1","acronym":"","url":"https://clinicaltrials.gov/study/NCT06385678","created_at":"2024-04-26T18:53:22.008Z","updated_at":"2024-07-02T16:35:07.335Z","phase":"Phase 1/2","brief_title":"A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation","source_id_and_acronym":"NCT06385678","lead_sponsor":"Jiangsu HengRui Medicine Co., Ltd.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • pemetrexed • AiRuiLi (adebrelimab) • HRS-4642 • tizetatug rezetecan (SHR-A1921)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 05/01/2024","start_date":" 05/01/2024","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-04-26"},{"id":"3389546b-7889-41d7-a623-1ac7e9ef8f61","acronym":"","url":"https://clinicaltrials.gov/study/NCT05924256","created_at":"2023-06-29T14:09:00.727Z","updated_at":"2024-07-02T16:35:14.639Z","phase":"Phase 2","brief_title":"A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing","source_id_and_acronym":"NCT05924256","lead_sponsor":"Fudan University","biomarkers":" HER-2 • AR","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification • HER-2 mutation • AR positive","tags":["HER-2 • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification • HER-2 mutation • AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e trastuzumab rezetecan (SHR-A1811) • leuprolide acetate for depot suspension • AiRuiEn (rezvilutamide) • tizetatug rezetecan (SHR-A1921)"],"overall_status":"Recruiting","enrollment":" Enrollment 88","initiation":"Initiation: 07/26/2023","start_date":" 07/26/2023","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2024-03-15"}]